백내장수술 후 건성안에서 레바미피드 2%와 히알루론산 0.15% 점안액의 병합투여 효과
Combined Effect of Rebamipide 2% and Hyaluronic Acid 0.15% on Dry Eye after Cataract Surgery
1
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
목적: 백내장수술 후 발생한 건성안에서 레바미피드 2%와 히알루론산 0.15% 점안액의 병합투여 효과를 알아보고자 한다. 대상과 방법: 백내장수술 후 1주일째 건성안에 대한 검사를 시행하여 건성안으로 진단된 환자에 대해 무작위로 선정한 병합투여군에는 레바피미드와 히알루론산점안액을 투여하였으며, 투여하지 않은 대조군과 비교하였다. 두 군에서 쉬르머검사, 눈물막파괴시간, 각막염색점수, 눈물막삼투압, 눈물지질층두께, 안구표면질환지수 등의 안구건조증검사를 수술 후 1개월째와 2개월째에 시행하였다. 결과: 병합투여군에서 수술 1개월째와 2개월째에 눈물막파괴시간(1개월째: p<0.001, 2개월째: p<0.001)과 각막염색점수(1개월째: p=0.001, 2개월째: p<0.001)의 유의한 호전을 보였다. 수술 후 1개월째와 2개월째에 눈물막파괴시간이 병합투여군이 대조군에 비해 유의하게 길었으며(p<0.001, p<0.001), 각막염색점수가 유의하게 낮았다(p=0.007, p<0.001). 결론: 백내장수술 후 레바미피드와 히알루론산점안액을 병합투여 시 눈물막파괴시간과 각막염색점수의 호전을 확인하였다.
Abstract
Purpose: To assess the combined therapeutic effects of topical rebamipide 2% and hyaluronic acid 0.15% in managing dry eye symptoms following cataract surgery. Methods: Patients who underwent cataract surgery (phacoemulsification with intraocular lens insertion) were assessed for dry eye one week following the procedure. Dry eye patients were randomly assigned to two groups: a treatment group receiving rebamipide 2% and hyaluronic acid 0.15% eye drops, and a control group who did not receive these treatments. Various dry eye tests, including Schirmer’s test, tear break up time (TBUT), ocular surface staining, tear film osmolarity, tear lipid layer thickness, and the ocular surface disease index, were conducted at one and two months after surgery. Results: Significant improvements in TBUT (1 month: p < 0.001; 2 months: p < 0.001) and ocular surface staining scores (1 month: p = 0.001; 2 months: p < 0.001) were observed in the treatment group at both one and two months after surgery compared to baseline. During the follow-up period, the treatment group consistently showed significantly longer TBUT (p < 0.001 at both intervals) and lower ocular surface staining scores (1 month: p = 0.007; 2 months: p < 0.001) when compared to the control group. Conclusions: The combined application of rebamipide and hyaluronic acid eye drops following cataract surgery effectively improved TBUT and ocular surface staining scores.
참고문헌 (26)
- Craig JP, "TFOS DEWS II definition and classification report", Ocul Surf, 15, pp.276~283 (2017)
- Gomes JAP, "TFOS DEWS II iatrogenic report", Ocul Surf, 15, pp.511~538 (2017)
- Miljanović B, "Impact of dry eye syndrome on vision-related quality of life", Am J Ophthalmol, 143, pp.409~415 (2007)
- Cho YK, "Dry eye after cataract surgery and associated intraoperative risk factors", Korean J Ophthalmol, 23, pp.65~73 (2009)
- Garg P, "Dry eye disease after cataract surgery : study of its determinants and risk factors", Turk J Ophthalmol, 50, pp.133~142 (2020)
- Hynnekleiv L, "Hyaluronic acid in the treatment of dry eye disease", Acta Ophthalmol, 100, pp.844~860 (2022)
- Kinoshita S, "Rebamipide(OPC-12759)in the treatment of dry eye : a randomized, double-masked, multicenter, placebo-controlled phase II study", Ophthalmology, 119, pp.2471~2478 (2012)
- Suh JH, "The effect of topical rebamipide 2% in managing dry eye following cataract surgery", J Korean Ophthalmol Soc, 65, pp.589~595 (2024)
- "HIRA Bigdata Open Portal" (2024)[URL]
- Kinoshita S, "A randomized, multicenter phase 3 study comparing 2% rebamipide(OPC-12759)with 0. 1% sodium hyaluronate in the treatment of dry eye", Ophthalmology, 120, pp.1158~1165 (2013)
- Cetinkaya S, "The course of dry eye after phacoemulsification surgery", BMC Ophthalmol, 15, pp.68~ (2015)
- Kim TH, "Effect of 0. 15% preservative-free sodium hyaluronate on dry eye disease after femtosecond laser-assisted cataract surgery", J Korean Ophthalmol Soc, 62, pp.922~930 (2021)
- Willcox MDP, "TFOS DEWS II tear film report", Ocul Surf, 15, pp.366~403 (2017)
- Kim MJ, "Clinical significance of tear film osmolarity in patients with mild dry eye syndrome", J Korean Ophthalmol Soc, 62, pp.295~299 (2021)
- Igarashi T, "Changes in tear osmolarity after cataract surgery", J Nippon Med Sch, 88, pp.204~208 (2021)
- González-Mesa A, "Role of tear osmolarity in dry eye symptoms after cataract surgery", Am J Ophthalmol, 170, pp.128~132 (2016)
- Dorennavar L, "The role of Rebamipide ophthalmic suspension in management of dry eye disease", Indian J Clin Exp Ophthalmol, 1, pp.191~196 (2015)
- Song JS, "Diagnosis and management of meibomian gland dysfunction", Ann Optom Contact Lens, 15, pp.37~39 (2016)
- Kim RY, "Correlation analysis of tear film lipid layer thickness and ocular surface disease index", J Korean Ophthalmol Soc, 58, pp.788~796 (2017)
- Han KE, "Evaluation of dry eye and meibomian gland dysfunction after cataract surgery", Am J Ophthalmol, 157, pp.1144~1150 (2014)
- Kashima T, "Rebamipide ophthalmic suspension for the treatment of dry eye syndrome : a critical appraisal", Clin Ophthalmol, 8, pp.1003~1010 (2014)
- Sánchez-González JM, "Lipid, aqueous and mucin tear film layer stability and permanence within 0. 15% liposome crosslinked hyaluronic acid versus 0. 15% non-crosslinked hyaluronic acid measured with a novel non-invasive ocular surface analyzer", J Clin Med, 11, pp.3719~ (2022)
- Ozcura F, "Ocular surface disease index for the diagnosis of dry eye syndrome", Ocul Immunol Inflamm, 15, pp.389~393 (2007)
- Nichols KK, "The lack of association between signs and symptoms in patients with dry eye disease", Cornea, 23, pp.762~770 (2004)
- Choi JH, "Effects of 0. 15% sodium hyaluronate on tear film and ocular surface disorders after vitrectomy surgery", Ann Optom Contact Lens, 20, pp.22~31 (2021)
- Igarashi T, "Improvements in signs and symptoms of dry eye after instillation of 2% rebamipide", J Nippon Med Sch, 82, pp.229~236 (2015)